Form 4: Rigel Pharmaceuticals Director Walter Moos Granted Equity Awards

Rigel Pharmaceuticals Inc. Director Walter H. Moos was granted 2,500 restricted stock units and options to purchase 3,000 shares of common stock on May 23, 2025, as part of his compensation.

Summary

• Walter H. Moos, a Director of Rigel Pharmaceuticals Inc. (RIGL), acquired equity securities on May 23, 2025.
• He was granted 2,500 shares of Common Stock through a Restricted Stock Unit (RSU) award, with a grant price of $0.
• He also acquired options to purchase 3,000 shares of Common Stock, with an exercise price of $18.95 per share.
• The RSU award is set to fully vest on the date prior to the Company's next Annual Meeting, contingent on his continuous service on the Board of Directors.
• The stock options will vest monthly over one year from the grant date, also subject to his continuous service on the Board of Directors, and have an expiration date of May 23, 2035.
• Following these transactions, Mr. Moos beneficially owns 12,722 shares of Common Stock and 3,000 stock options.
• The reported beneficial ownership of Common Stock has been adjusted to reflect a one-for-ten reverse stock split that became effective on June 27, 2024.

Sentiment

Score: 7

Explanation: The filing indicates a director's receipt of equity compensation, which is a positive sign of alignment between management and shareholder interests, though it's a routine compensation event rather than a significant operational or financial milestone.

Positives

• The granting of equity awards to a director, Walter H. Moos, aligns his interests with those of the shareholders, as his compensation is tied to the company's stock performance.
• The RSU award was granted at a price of $0, indicating it is a direct compensation component.

Risks

• The vesting of both the Restricted Stock Units and the stock options is contingent upon Walter H. Moos's continuous service on the Company's Board of Directors, meaning the awards could be forfeited if his service ceases prematurely.

Future Outlook

The Restricted Stock Units are expected to fully vest on the date prior to the Company's next Annual Meeting, and the stock options will vest monthly over one year from the grant date, both subject to the director's continuous service.

Management Comments

• The filing was signed by Raymond Furey as Attorney-in-Fact for Walter H. Moos.

Industry Context

The granting of equity awards to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of compensation and a mechanism to align the interests of board members with those of shareholders.

Related Party Transactions

• The equity grants to Director Walter H. Moos constitute related party transactions, as they involve compensation from the company to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest on the date prior to Rigel Pharmaceuticals' next Annual Meeting.
• The stock options will vest monthly over a one-year period from the grant date of May 23, 2025.

Key Dates

Recommendation

Keywords

Rigel Pharmaceuticals, RIGL, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Reverse Stock Split